Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brazikumab - AstraZeneca

Drug Profile

Brazikumab - AstraZeneca

Alternative Names: AMG-139; Brazikumab-Allergan; MEDI-2070

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Amgen; AstraZeneca
  • Class Anti-inflammatories; Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action Interleukin-23 subunit p19 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Psoriasis
  • Discontinued Crohn's disease; Ulcerative colitis

Most Recent Events

  • 10 Oct 2023 AstraZeneca terminates the phase II EXPEDITION OLE trial in Ulcerative colitis (Treatment-experienced) in USA, Austria, Czech Republic, Germany, Hungary, Israel, Italy, Japan, South Korea, Poland, Puerto Rico, South Africa, Spain and Taiwan, due to a strategic decision to discontinue the development of the drug in Inflammatory bowel diseases (NCT04277546) (EudraCT2021-001644-10)
  • 16 Jun 2023 Discontinued - Phase-II/III for Crohn's disease in United Kingdom (IV)
  • 08 Jun 2023 Discontinued - Phase-II for Crohn's disease in Germany, Czech Republic, Hungary, France, Spain, Italy, Poland, Bulgaria, Belgium, Australia, Israel, Netherlands, Russia (SC)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top